Worldwide

HD-tDCS Accessories

The only electrodes validated for HD-tDCS

After brain targeting, the fundamental innovation of HD-tDCS are the “High-Definition” electrodes: designed for safe and tolerated stimulation - every time. The use of Soterix HD-tDCS electrodes is thus essential to ensure subject protection. Every Soterix Medical HD electrode are compatible only with Soterix Medical stimulators.

Choosing the right High Definition (HD) electrode holder for your application is easy. Every electrode holder is rated for stimulation capacity, allowing you to reliably select the electrode holder that matches your trial design. HD1 models are rated for single sessions of up to 2 mA and 22 minutes while HD-M models are rated for multiple sessions of up to 1 mA.

HD-tDCS is naturally compatible with EEG and Soterix Medical HD-tDCS allow you to use any EEG system. This means you get combine Soterix HD-tDCS technology with the EEG systems you know and trust to ensure EEG data collection is research quality. Soterix Medical HD electrodes are “generically” compatible with EEG systems or designed to be compatible with specific EEG systems as specified.

Soterix provides accessories for HD-tDCS that replaces the “pads” used in conventional tDCS. In fact, HD-tDCS accessories can also be used with Soterix 1×1 tDCS systems. But only when using in combination with HD-tDCS Stimulators can the full potential of HD-tDCS, be achieved.

HD-tDCS Electrodes

Soterix Medical HD-cap fully loaded with HD electrode holders

Manual & Specifications

HD1 electrode holder: Rated for single sessions up to 2 mA and up to 22 minutes. Gel: Signa or HD-GEL (CCNY4). Only approved held and electrode models are validated. Allow generic integration with most EEG commercial systems.

HDM electrode holder. Rated for multiple sessions up to 2 mA and up to 22 minutes for 5 sessions per week Gel: Signa or HD-GEL (CCNY4). Only approved held and electrode models are validated. Allow generic integration with most EEG commercial systems.

HD1-Biosemi electrode holder. Rated for single sessions up to 2 mA and up to 22 minutes. Gel: Signa or HD-GEL (CCNY4). Only approved held and electrode models are validated. Can be integrated with Biosemi recording system.

HDM-Biosemi electrode holder. Rated for multiple sessions up to 2 mA and up to 22 minutes for 5 sessions per week. Gel: Signa or HD-GEL (CCNY4). Only approved held and electrode models are validated. Can be integrated with Biosemi recording system.

Revolutionary Neurotargeting Software

Optimization of electrode montage for brain targeting and individual subject customization has never been as easier as with Soterix Medical's Neurotargeting software. With recognition that placing an electrode "over" a target dose not support rational tDCS does design, the Soterix Medical Suite of software tools allow simple and automatic optimization. Soterix Neurotargeting software also provides high-resolution current flow visualization that can be used to support publications, presentation and proposals.

Explore Software Solutions »

Advanced real-time control and optimization

Clinical Trials

tDCS for the Treatment of Bipolar Depression

Soterix Medical 1x1 Clinical Trials device with Limited Total Energy (LTE) to be used in a trial to study the antidepressant effects of tDCS in bipolar disorder.

tDCS and Talking Therapy for Aphasia

Hunter College of The City University of New York will investigate the use of Soterix Medical 1x1 tDCS (transcranial direct current stimulation) in conjunction with speech-language therapy, for the improvement of language production in stroke survivors with aphasia.

Phase III Clinical Trial for major depressive disorder

Trial will compare Soterix Medical tDCS-LTE™ technology against a fully dosed, effective antidepressant Escitalopram oxalate (Lexapro). Recruitment ongoing.
Soterix Medical 1×1 Clinical Trials (CT) device using Limited Total Energy (LTE™) technology is being used in the study.

Effects of tDCS on Motor Learning in Children With Cerebral Palsy (CP)

Trial will assess the clinical and neurophysiological effects of a non-invasive brain stimulation technique - transcranial direct current stimulation (tDCS)- on cortical plasticity and motor learning in children with cerebral palsy.

Cognitive Stimulation Study (CogStim)

This study will evaluate the influence of non-invasive brain stimulation on different elements of cognitive function in healthy persons between the ages of 18-90 years. Soterix Medical 1×1 tDCS device is being used in this study.

Neuropathic Symptoms Following Burn Injury Trial

Spaulding Rehabilitation Hospital and the US Department of Education will investigate the effects of Soterix Medical 1x1 transcranial direct current stimulation (tDCS) on the pain and itching associated with burn injury. This study is part of the Boston-Harvard Burn Model System.

Phase II Fibromyalgia Trial

Follow up Phase II, HD-tDCS clinical trial underway for fibromyalgia at Harvard Medical School and Spaulding Rehabilitation Hospital, and in conjunction with Elminda Corporation. Exclusive Soterix 4x1 HD-tDCS being used.

Abdominal pain in patients with chronic pancreatitis Clinical Trial

This study is testing whether the addition Soterix Medical 1x1 transcranial direct current stimulation (tDCS) when combined with meditation helps decrease the abdominal pain in patients with chronic pancreatitis.

Corneal Pain Clinical Trial

Study focused on investigating effect of tDCS on chronic corneal pain as well as changes in thought processing as compared to healthy controls. Soterix 1×1 Device is being used.

Stroke Recovery Clinical Trial

Study focused on evaluating the effect of a combination of robotic arm therapy and transcranial Direct Current Stimulation for greater functional recovery after stroke.

Depression Clinical Trial

For the most comprehensive tDCS trial to-date, researchers selected the most advanced tDCS device and the only system optimized for clinical trials – The Soterix Medical 1x1-CT.

Pediatric Epilepsy Trial

Epilepsy Foundation awards a New Therapy Grant for a clinical trial of High-Definition tDCS in pediatric epilepsy. Dr. Alexander Rotenberg will lead a team of clinical investigators including at BCH and Harvard Medical School.

Stroke Rehabilitation Trial

NIH grants Burke Medical Research Institute $3m to conduct the most controlled trial of tDCS for stroke rehabilitation to date. The Soterix Medical 1x1 platform is the most advanced and the industry standard for tDCS clinical trials for rehabilitation.

Down Syndrome Trial

Soterix Medical Inc. receives FDA Clinical Trial IDE for High-Definition tDCS (HD-tDCS) to improve IQ in pediatric Down syndrome. HD-tDCS is the only non-invasive, brain targeted, and low-intensity technology designed to promote neuroplasticity.

Pediatric Hemiparesis Trial

Dr. Bernadette Gillick's Pediatric Rehabilitation Laboratory is supported by the NIH and University of Minnesota Clinical and Translational Science Institute to investigate the use of a form of tDCS for interventions in rehabilitation for children. Subject specific analysis with Soterix Medical Neurotargeting™ will guide current to brain cells in the injured part of the brain.

Fibromyalgia Clinical Trial

HD-tDCS clinical trial underway for fibromyalgia at Harvard Medical School and Spaulding Rehabilitation Hospital, Boston.

Stroke Rehabilitation Clinical Trial

NIH grants Soterix a Phase-1 STTR grant to develop HD-tDCS for stroke rehabilitation. The first technology capable of delivering therapeutic direct current to target brain regions involved in functional recovery.

Caution! Investigational Device. Federal (or United States) law limits device to investigational use.